South Korea · Health Care · KRW (Thousands) · Annual
Key financials
KRW|Thousands
ROE
-186.97%
2025 (actual)
ROA
-108.42%
2025 (actual)
Gross Margin
81.73%
2025 (actual)
Net Margin
-
Total Assets
₩55,797,789.12K
2025 (actual)
Net Income
-₩42,024,660.5K
2025 (actual)
Valuation
₩347,578,054.9K
2026 (forecast)
Stock Price
₩22,900
Historical & projected performance
KRW|Thousands
Reported figures and Equlion model projections for the next 5 years.
ROE
+219.9 pt
Company
ROA
-68.9 pt
Company
Gross Margin
-7.1 pt
Company
Sector average
Total Assets
+60%
Company
Sector average (own scale)
Net Income
-265%
Company
Sector average (own scale)
Valuation
+145.9%
Company
Sector average
Stock Price
+145.9%
Company
Sector average
Amounts in KRW (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Y-Biologics? It covers the balance sheet, income statement, cash flow and Equlion model projections.